Sermorelin dosing: what the label said and what the trials used

The short version: doses in the record

This page documents doses as they appear in the historic FDA-approved label and in published research trials. It is not a recommendation, and there is no current FDA-approved adult sermorelin product.

The pediatric label set a once-daily subcutaneous dose of 30 micrograms per kilogram of body weight at bedtime — timed to reinforce the body's natural overnight GH pulse. Adult research used a range of regimens, from twice-daily injections in a two-week study of older men to nightly injections in a 16-week body-composition trial. A related GHRH analog was used nightly for 20 weeks in cognitive trials.

Sermorelin is cleared from the blood in roughly 11 to 12 minutes, which is by design: the molecule is built to produce a short, discrete GH pulse rather than continuous receptor stimulation. That short half-life is also why longer-acting analogs were developed.

Reading note

This page documents the doses that appear in the historic FDA-approved labeling and in the published research literature. It is not a recommendation. There is currently no FDA-approved finished sermorelin product on the U.S. market; all access in 2026 is through 503A or 503B compounding pharmacies on the basis of an individual patient prescription, and any dosing decision is the responsibility of the prescribing clinician working from current professional sources. The values below are reproduced because they are part of the public record of what has been studied — not because the site is suggesting any particular regimen.

Historic FDA-labeled pediatric regimen

The 1997 FDA-approved sermorelin acetate injection carried an indication for the treatment of idiopathic growth hormone deficiency in children with growth failure. The labeled regimen was 30 µg/kg subcutaneous once daily at bedtime ^[1][2][6].

The bedtime timing was deliberate. Endogenous GH secretion is pulsatile, with the largest physiologic pulses during slow-wave sleep; the nightly subcutaneous dose was designed to reinforce the natural nocturnal pulse pattern rather than to drive continuous receptor stimulation.

The pivotal trial of this regimen — Thorner and colleagues (1996), an international multicenter study published in JCEM — reported mean height velocity rising from 4.1 ± 0.9 cm/yr at baseline to 8.0 ± 1.5 cm/yr at six months in 74% of treated children ^[1]. The contemporary BioDrugs review (Prakash and Goa, 1999) reported the same regimen sustaining catch-up growth through twelve months in the majority of prepubertal GHD children ^[2].

Historic FDA-labeled diagnostic regimen

Sermorelin's second FDA-approved indication was diagnostic. A 1 µg/kg intravenous bolus was administered for provocative evaluation of pituitary GH secretory capacity, with serum GH measured at intervals afterward. In the historic literature this functioned as a relatively specific GH provocative test with fewer false positives than other stimulation modalities ^[2][6].

A 2024 review of adult GHD diagnostic practice notes that the worldwide commercial unavailability of pharmaceutical GHRH over the prior decade has materially changed the diagnostic landscape — the GHRH + arginine and GHRH + GHRP-6 stimulation tests, once standard, are no longer feasible through standard pharmaceutical channels in many jurisdictions ^[14].

Adult aging-axis research doses

Two adult controlled trials anchor the somatopause dosing record:

• Corpas et al. 1992 — healthy men aged 60-78, 0.5 mg or 1.0 mg subcutaneous twice daily for 14 days. The 1 mg dose restored mean 24-hour GH, peak GH amplitude, and IGF-1 to values not significantly different from healthy young men. Elevated IGF-1 persisted approximately two weeks after dosing stopped ^[3].
• Khorram et al. 1997 — adults aged 55-71 (n=19), nightly subcutaneous [Nle27]GHRH(1-29)-NH2 at 10 µg/kg for 16 weeks after a 4-week placebo lead-in. Increased lean mass and skin thickness, improved insulin sensitivity in men ^[4].

A related cognitive trial used tesamorelin 1 mg subcutaneous nightly for 20 weeks in adults aged 55-87 — a stabilized GHRH analog rather than sermorelin proper, but mechanistically equivalent ^[7].

These doses are research-context values from published controlled trials. They are not labeled doses (there is no current adult sermorelin labeling) and they are not transferable to clinical practice without independent professional evaluation.

Pharmacokinetics: short half-life by design

Sermorelin is rapidly absorbed and rapidly cleared. Plasma clearance in adults is approximately 2.4-2.8 L/min. Terminal half-life is approximately 11-12 minutes after either intravenous or subcutaneous administration ^[6].

The short half-life is the design intent, not a limitation. The molecule is meant to produce a discrete physiologic GH pulse rather than sustained receptor stimulation, mimicking endogenous pulsatile GHRH signaling. Sustained GHRH-R occupancy would defeat the somatostatin and IGF-1 feedback structure that gives the molecule its self-limiting safety character ^[15].

It is also the principal reason that structurally stabilized analogs exist. CJC-1295 (no DAC, also called Modified GRF 1-29) substitutes amino acids in the GHRH(1-29) sequence to resist DPP-IV degradation and extend functional half-life. Tesamorelin is a separately stabilized analog that has been FDA-approved for HIV-associated lipodystrophy and used as the proxy molecule in several cognitive trials. Sermorelin itself remains the canonical pulsatile-stimulation choice where strict mimicry of endogenous GHRH pharmacokinetics is the design intent.

Routes studied

Three administration routes appear in the literature:

• Subcutaneous injection — by far the most common, used in both the pediatric efficacy trials and the adult somatopause and cognitive trials.
• Intravenous bolus — historically used for the diagnostic GH stimulation test only.
• Sublingual or oral troche — appears in some compounded research formulations; bioavailability is less well characterized in peer-reviewed sources.

The peptide is supplied as a lyophilized powder requiring reconstitution. Reconstituted solutions are typically refrigerated at 2-8 °C and used within a defined window per compounding pharmacy assignment. The peptide is sensitive to heat and to repeated freeze-thaw cycles.

Safety profile in the FDA-era trial record

The FDA-era safety record is mild and stereotyped. The most common treatment-related adverse event in pediatric clinical-trial datasets was a transient injection-site reaction (pain, swelling, or redness) occurring in approximately 1 of 6 patients. Other events reported at individual rates below 1% included headache, facial flushing, dysphagia, dizziness, hyperactivity, somnolence, and urticaria. No clinically significant changes in serum chemistries, thyroid function, or glucose tolerance were observed over the trial period ^[10].

The historic label listed two principal contraindications: active malignancy and unevaluated pituitary mass. Long-term elevation of IGF-1 has been associated in epidemiologic studies with theoretical increases in malignancy risk; causality remains debated, and most research protocols monitor IGF-1 and target the upper-normal age range rather than supraphysiologic values ^[11].

A hypothalamic GHD diagnosis cannot be ruled out by a normal sermorelin stimulation test result, because sermorelin acts at the pituitary downstream of the hypothalamus; diagnostic interpretation requires clinical context.